Cover Image

全球惡性黑色素瘤 (MM) 治療藥市場、臨床實驗平台分析

Global Malignant Melanoma Drug Market & Clinical Pipeline Insight

出版商 KuicK Research 商品編碼 357206
出版日期 內容資訊 英文 500 Pages
商品交期: 最快1-2個工作天內
Back to Top
全球惡性黑色素瘤 (MM) 治療藥市場、臨床實驗平台分析 Global Malignant Melanoma Drug Market & Clinical Pipeline Insight
出版日期: 2016年05月05日 內容資訊: 英文 500 Pages

本報告提供全球惡性黑色素瘤 (MM) 治療藥市場相關調查分析,市場概要,作用機制,臨床實驗平台 (各企業,各相位) 、臨床實驗平台,上市產品等相關的系統性資訊。

第1章 惡性黑色素瘤 (MM) 概要

第2章 惡性黑色素瘤 (MM) 治療藥的作用機制

第3章 全球惡性黑色素瘤 (MM) 市場分析

  • 目前市場方案
  • 全球惡性黑色素瘤 (MM) 開發平台概要

第4章 全球惡性黑色素瘤 (MM) 治療藥的市場動態

  • 有利的市場參數
  • 商業化的課題

第5章 全球惡性黑色素瘤 (MM) 治療藥市場未來發展預測

第6章 全球惡性黑色素瘤 (MM) 治療藥的臨床實驗平台:各企業,各相位

  • 階段不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 登記完畢

第7章 全球已上市惡性黑色素瘤 (MM) 治療藥臨床分析

第8章 競爭情形

  • AB Science
  • Celgene Corporation (Abraxis BioScience)
  • Array BioPharma
  • AVAX Technologies
  • Biogen Idec
  • BioVex
  • Bristol-Myers Squibb
  • Enzon Pharmaceuticals
  • Eisai
  • Exelixis
  • GlaxoSmithKline
  • Lorus Therapeutics (Aptose Bioscience)
  • Medarex
  • Merck
  • Navidea Biopharmaceuticals
  • Novartis
  • 小野藥品工業
  • Onyx PharmaceOuticals
  • Pfizer
  • Pharmalucence (Sun Pharmaceutical Industries Limited)
  • Plexxikon
  • Roche
  • Reliance Life Sciences
  • Servier
  • TC BioPharm
  • Viragen



Investigators are trying to develop innovative therapeutics for the treatment of malignant melanoma with high safety and efficacy. Surgery has remained the corner stone of cancer treatment including malignant melanoma. Cancerous region and adjoining tissue is removed to prevent it growth. Radiation therapy is also found to be effective in melanoma treatment but it causes long-tern deleterious effects on body. Chemotherapeutics can prevent malignant cancer but it side effects decrease quality of life and increase morbidity. It has been found that cancerous cells develop changes to evade the effect of the therapeutics leading to less efficacy. These facts are required to be overcome in near future and investigators are trying to develop different modalities. Some progress has been made which is expected to increase the market size of malignant melanoma.

Research and development of malignant melanoma therapeutics has gained lots of attention in past few decades due to rapidly increasing incidences. Large numbers of clinical trials have been instigated to find an effective therapeutics having high safety and efficacy levels. Various products are at different stages of clinical trials which would be introduced in coming years. Their safety and efficacy is prime concern because investigators are still trying to understand exact mechanism behind factors leading to the development of malignant melanoma. For instance, signaling pathways are complex and intertwined making it difficult for investigators to rely on single approach to treat malignant melanoma. In coming years, it is expected that investigators would be able to identify these factors resulting in development of pharmacologically superior products offering higher safety and efficacy profiles.

Malignant melanoma cells have been found to have changes in genes due to which they spread across the body. It has been found that genes like BRAF are mutated in certain individuals. By blocking their activity it would be possible to prevent the development of malignant melanoma. Side-by-side, identification of aberration in such genes will allow the investigators to identify individuals with high possibility of its development. Physicians would be able to device effective therapeutic strategies to offer better medical care. Several drug target candidates have yet to be discovered and checked for their efficacy against activity of such genes. Blocking of gene activity is difficult as their expression levels keep on changing depending upon physiological activities. Most of the studies are at incipient stages which are expected to take some time in commercialization.

Many innovative therapeutics are at various phases of clinical trials for malignant melanoma treatment. They are expected to generated statistically significant data encouraging pharmaceutical companies to proceed with higher levels of confidence. The long-term effect of these innovative therapeutics is under investigation, sufficiently high safety and efficacy data will make it easy to apply for marketing approval in different countries. In few years, owing to rapidly developing clinical pipelines, innovative malignant melanoma therapeutics are expected to enter in global market leading to increase in their market size. Future commercial success of these novel products seems to be optimistic but their commercialization may take some years.

“Global Malignant Melanoma Drug Market & Clinical Pipeline Insight” Report Highlight:

  • Global Malignant Melanoma Market Analysis
  • Malignant Melanoma Drug Mechanism of Action
  • Global Malignant Melanoma Clinical Pipeline By Company & Phase
  • Global Malignant Melanoma Clinical Pipeline: 201 Drugs
  • Majority Malignant Melanoma Drugs in Preclinical Phase: 63 Drugs
  • Global Malignant Melanoma Marketed Drugs Clinical Insight
  • Marketed Malignant Melanoma Drugs: 25 Drugs

Table of Contents

1. Introduction to Malignant Melanoma

2. Malignant Melanoma Drug Mechanism of Action

3. Global Malignant Melanoma Market Analysis

  • 3.1. Current Market Scenario
  • 3.2. Global Malignant Melanoma Pipeline Overview

4. Global Malignant Melanoma Drug Market Dynamics

  • 4.1. Favorable Market Parameters
  • 4.2. Commercialization Challenges

5. Global Malignant Melanoma Drug Market Future Prospects

6. Global Malignant Melanoma Clinical Pipeline By Company & Phase

  • 6.1. Unknown
  • 6.2. Research
  • 6.3. Preclinical
  • 6.4. Clinical
  • 6.5. Phase-I
  • 6.6. Phase-I/II
  • 6.7. Phase-II
  • 6.8. Phase-II/III
  • 6.9. Phase-III
  • 6.10. Registered

7. Global Malignant Melanoma Marketed Drugs Clinical Insight

  • 7.1. Talimogene Laherparepvec (IMLYGIC)
  • 7.2. Nivolumab (Opdivo)
  • 7.3. Temozolomide (Temodal & Temodar)
  • 7.4. Peginterferon alfa-2b (Cylatron, Intron A Peg, PEG-Intron A, Pegatron, Pegintron, Pegtron & ViraferonPeg )
  • 7.5. Pembrolizumab (Keytruda )
  • 7.6. Vemurafenib
  • 7.7. Ipilimumab (Yervoy)
  • 7.8. Cobimetinib (Cotellic)
  • 7.9. Trametinib (Mekinist)
  • 7.10. Tc 99m Tilmanocept (Lymphoseek)
  • 7.11. Dabrafenib (Tafinlar)
  • 7.12. Aldesleukin (Chiron IL-2 & Proleukin)
  • 7.13. Interferon alpha-2b (Intron A, Viraferon & Virtron)
  • 7.14. Interferon-beta-1b - Toray/Daiichi Sankyo (Feron)
  • 7.15. Melanoma Vaccine - AVAX Technologies (MVax)
  • 7.16. Interferon alpha - Swedish Orphan Biovitrim (Multiferon)
  • 7.17. Interferon alpha-2b - Beijing Kawin Technology
  • 7.18. Virulizin (Virulizin)
  • 7.19. Vemurafenib Companion Diagnostic - Roche/Plexxikon (cobas 4800 BRAF V600 Mutation Test)
  • 7.20. Dabrafenib-Trametinib Companion Diagnostic - bioMerieux/ GlaxoSmithKline/ Response Genetics (THxID-BRAF)
  • 7.21. Interferon alpha-2b Biosimilar - Reliance Life Sciences (ReliFeron)
  • 7.22. Technetium Tc 99m Sulfur Colloid Injection - Pharmalucence
  • 7.23. Interferon alpha-2a (Roferon-A)
  • 7.24. Fotemustine (Muforan, Muphoran, Mustoforan & Mustophoran)
  • 7.25. Melanoma Vaccine - GlaxoSmithKline (Melacine)

8. Competitve Landscape

  • 8.1. AB Science
  • 8.2. Celgene Corporation (Abraxis BioScience)
  • 8.3. Array BioPharma
  • 8.4. AVAX Technologies
  • 8.5. Biogen Idec
  • 8.6. BioVex
  • 8.7. Bristol-Myers Squibb
  • 8.8. Enzon Pharmaceuticals
  • 8.9. Eisai Co
  • 8.10. Exelixis
  • 8.11. GlaxoSmithKline
  • 8.12. Lorus Therapeutics (Aptose Bioscience)
  • 8.13. Medarex
  • 8.14. Merck
  • 8.15. Navidea Biopharmaceuticals
  • 8.16. Novartis
  • 8.17. Ono Pharmaceutical
  • 8.18. Onyx Pharmaceuticals
  • 8.19. Pfizer
  • 8.20. Pharmalucence (Sun Pharmaceutical Industries Limited)
  • 8.21. Plexxikon
  • 8.22. QIAGEN
  • 8.23. Roche
  • 8.24. Reliance Life Sciences
  • 8.25. Servier
  • 8.26. TC BioPharm
  • 8.27. Viragen

List of Figures

  • Figure 1-1: Causes behind Development of Skin Cancer
  • Figure 1-2: Different Melanomas on the basis of Histology
  • Figure 2-1: Mechanism of Dacarbazine
  • Figure 2-2: Mechanism of Vemurafenib
  • Figure 2-3: Mechanism of Ipilimumab
  • Figure 2-4: Mechanism of Nivolumab
  • Figure 3-1: Global Malignant Melanoma Drug Market (US$ Billion), 2015-2020
  • Figure 3-2: Global Malignant Melanoma Drug Pipeline by Phase (%), 2016
  • Figure 3-3: Global Malignant Melanoma Drug Pipeline by Phase (Numbers), 2016
  • Figure 4-1: Malignant Melanoma Drug Market Favorable Features
  • Figure 4-2: Malignant Melanoma Drug Market Commercialization Challenges
  • Figure 8-1: AB Science Clinical Pipeline
  • Figure 8-2: Malignant Melanoma Clinical Pipeline
  • Figure 8-3: Aptose Biosciences Pipeline
  • Figure 8-4: Merck Clinical Pipeline
  • Figure 8-5: Novartis Clinical Pipeline
  • Figure 8-6: Plexxikon Clinical Pipeline
  • Figure 8-7: Roche Clinical Pipeline
Back to Top